Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study.

Trial Profile

Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2011

At a glance

  • Drugs Ondansetron (Primary)
  • Indications Obsessive-compulsive disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2009 Results published in CNS Drugs.
    • 21 May 2009 Status changed from recruiting to completed, according to a Transcept Pharmaceuticals media release.
    • 21 May 2009 Results will be presented in a poster at the annual meetng of the American Psychiatric Association (APA), according to a Transcept Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top